INTRODUCTION
The observation of a low percentage of mature oocytes after administration of 10,000 IU of human chorionic gonadotropin (hCG) in some patients with fulfillment of the follicular maturation parameters is difficult to explain. Ndukwe et al. (1) B-hCG is predictive of empty follicle syndrome before oocyte retrieval, with a cutoff point of 10 IU/L, 36 hr post-hCG administration. However, no observation has been published for the possible effect of different blood levels (above 10 IU/L) of hCG on the maturation of oocytes. With regard to whether the dose of hCG is sufficient for final oocyte maturation, Fisher et al. (2) demonstrated that when a group of women received hCG intravenously, 500 IU resulted in a mean serum concentration of 45 IU/L after 21 hr and 23 IU/L after 35 hr. These concentrations resulted in ovulation. Wikland et al. (3) have shown that hCG can be given subcutaneously without reducing the chance of retrieving a mature oocyte. They reported that the mean concentration of hCG in serum 12 and 36 hr after hCG injection was significantly higher in the women receiving 5000 IU intramuscularly compared with subcutaneously. However, their data about oocyte maturity exhibit no difference between the groups administered hCG intramuscularly and subcutaneously in those who had received 5000 or 10,000 IU of hCG. It thus seems as though rather low concentrations of hCG will induce oocyte maturity and even ovulation. The extent to which variation in mature oocytes recovered is determined by variation in hCG uptake and metabolism is unknown and forms the basis of this study.
MATERIALS AND METHODS

Follicular Stimulation and hCG Administration
The gonadotropin-releasing hormone agonist (GnRH-a) Suprefact (Hoechst, Hounslow, UK) was administered by subcutaneous injection at a dosage of 500 (Ug/day or as a nasal spray with a dosage of two sprays per nostril every 8 hr. The protocols used were either short or long. In both regimens GnRH-a is administered daily until the injection of hCG. In all regimens ovarian follicular growth and development were stimulated with daily injection of human menopausal gonadotropin (hMG; Pergonal, Serono, Welwyn Garden City, UK, or Humegon, Organon Laboratories, Cambridge, UK) until the administration of hCG. Based on age, weight, and previous response, patients were given either 150, 225, or 300 IU of hMG.
The criteria for hCG (Profasi, Serono, or Pregnyl, Organon Laboratories) administration were the presence of three or more follicles of 18 mm or greater in mean diameter and that serum estradiol levels had been steadily rising and were consistent with the number of follicles observed by ultrasound. hCG, 10,000 IU, was administered by a single intramuscular injection 36 hr prior to planned oocyte collection.
Blood Specimen Collection and Preparation for Analysis
Three samples of blood were obtained at different times after administration of hCG as follows: (a) 12 hr after hCG administration; (b) 36 hr, during oocyte recovery while the patient is under general anesthesia; and (c) 84 hr, when the patient comes for embryo transfer and prior to Gestone injection.
hCG Assay
The IMx total B-hCG assay (Abbott Diagnostics) was used for analysis of serum hCG in this study. It is a microparticle enzyme immunoassay for the quantitative and qualitative determination of B-hCG in human serum and plasma.
Oocyte Classification
Ultrasound-directed oocyte retrieval using a transvaginal transducer is performed 36 hr following hCG administration. The morphology of the oocytecumulus complex was examined under an inverted microscope with phase-contrast optic (Olympus IMT2) after cumulus cells were removed. They were classified as mature (metaphase-II [MII], one polar body), immature (intact germinal vesical [GV] ; and metaphase-I [MI]; no GV, no polar body), or abnormal on the basis of morphology and the appearance of the associated granulosa cells at aspiration. All the mature oocytes were microinjected with a single sperm.
Informed written consent was obtained from each participating couple, and the study had the approval of the NURTURE Ethical Committee at the Queen's Medical Centre, Nottingham. Statistical comparisons between groups were made by application of Student's t-test.
RESULTS
A total of 404 patients was recruited prospectively between April 1996 and March 1997. Their mean age was 33 years; 2.7% were aged younger than 25, 26.5% were aged 25-30 years, 48% were aged 30-35 years, 17% were aged 36-39 years, and 5.8% were aged 40-42 years. The long and short protocols were used in 338 (84%) and 66 (16%) patients, respectively.
hCG Results
Twelve hours after intramuscular hCG administration, serum hCG levels were 51-644 IU/L (mean, 204.20 IU/L). Thirty-six hours later, serum hCG levels were 45-442 IU/L (mean, 146.51 IU/L). After 84 hr, serum hCG levels were 9-172 IU/L (mean, 60.04 IU/ L). The serum half-life of hCG is 48 hr (Table I) .
Recovery of Oocytes
A total of 5036 oocytes was retrieved in 404 patients (an average of 12 oocytes per patient). Of all the oocytes retrieved, 4252 (85%) were MII, 293 (6%) were GVs, 261 (5%) were MI and 219 (4%) were classified as having various degenerative changes (as defined under Materials and Methods).
Mature Oocytes
The mean percentage of MII oocytes at different blood levels ranges from 84 to 88%. The general trend does not show any significant increase in percentage of MII oocyte in association with an increasing serum hCG concentration (Table II) . 
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Immature and Abnormal Oocytes
The mean percentage of immature oocytes varies between 3.8 and 6.4%. The general trend does not show any significant changes in the percentage of MI, GV, or abnormal oocytes in association with an increasing serum hCG concentration (Table II ).
DISCUSSION
The critical blood level of hCG capable of producing a maturational effect on the oocyte cannot be determined precisely. However, the results of this study suggest that at 12, 36, and 84 hr after hCG administration, levels as low as 50, 45, and 9 IU/ L, respectively, are equally potent as the higher levels at initiating maximal oocyte maturity. This is pertinent given concern about the effect of excessive levels of plasma hCG on implantation and pregnancy (4) . The longer serum half-life of hCG presents certain clinical disadvantages following ovarian stimulation (5). These include errors in early detection of pregnancy due to residual exogenous HCG, increased risk of ovarian hyperstimulation syndrome, and development of multiple corpora lutea that produce superphysiological concentration of progesterones and estradiol.
This observation also raises the question as to the role of massive hCG blood levels obtained after a 10,000 IU intramuscular injection of hCG. It has been shown in nonhuman primates that the administration of 3-to 10-fold lower doses of hCG elicited some periovulatory responses that were equivalent to those induced by 1000 IU hCG (6) .
Oocyte maturation can be achieved with hCG doses of lesser amplitude or duration than those required for follicular rupture and luteal development and function (7) (8) (9) . In assisted reproduction programs, such as human in vitro fertilization, hCG is not given primarily to achieve ovulation but rather to induce final oocyte maturation prior to aspiration.
Why intramuscular hCG injection leads to variable serum levels is not understood. The differences between the bioactivity in different batches of hCG ampoules could be a contributing factor (10) . The empty follicle syndrome is a condition characterized by a failure in the recovery of identifiable oocytes after aspiration and thorough flushing of follicles subjected to controlled ovarian stimulation for in vitro fertilization and embryo transfer. It has been shown that empty follicle syndrome is not a consequence of an ovarian problem but the result of a lack of exposure to biologically active hCG (10) . In that study, Zegers-Hochschild et al. suggested the possibility that an abnormality in the manufacture, packing, or shelf life of the drug could have caused desialylation of hCG. However, erratic absorption and differences in metabolism and clearance cannot be excluded. Therefore, one might expect a large and wide variation in the hCG serum concentration between different patients. It is interesting to note that hCG does not inhibit the subsequent spontaneous luteinizing hormone (LH) surge by the intact pituitary, confirming that an ultrashort-loop feed-back of LH (here, hCG) on its own secretion is not functional (11) . Increased progesterone levels immediately after hCG administration have been found subsequently to induce an endogenous pituitary LH surge in clomophine citrate and hMG cycles (12) . For this reason, the contribution of LH to the maturity of the eggs cannot be ruled out in this study. This can be the subject of a follow-up study. It would appear that oocyte maturation induction sets in when the plasma level of hCG is relatively low. During in vitro fertilization cycles, a large bolus of hCG is used to induce periovulatory events, but the efficacy of lower doses is undefined. Therefore, a lower dose regimen of hCG may be useful for induction of periovulatory events in certain patient's undergoing in vitro fertilization.
